TriSalus Life Sciences, Inc. (TLSI) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, TriSalus Life Sciences, Inc.'s filing signal turned negative.

TriSalus Life Sciences is an oncology-focused medical technology company aiming to improve patient outcomes for solid tumors by integrating its Pressure-Enabled Drug Delivery (PEDD) technology with standard therapies and its investigational immunotherapeutic, nelitolimod. The company's core technology, the TriNav Infusion System, is a 510(k)-cleared device used in interventional radiology for procedures like transarterial radioembolization (TARE) and transarterial chemoembolization (TACE), primarily for liver cancer. TriNav's SmartValve technology modulates pressure and flow to enhance therapeutic delivery into tumors, demonstrating improved tumor deposition and reduced non-target embolization in clinical studies. TriSalus is also developing a pancreatic retrograde venous infusion (PRVI) device for pancreatic tumors and is advancing nelitolimod, a TLR9 agonist, in clinical trials for various solid tumors. The company generated $45.2 million in TriNav revenue in 2025, a 53.4% increase year-over-year, and is expanding its PEDD technology applications into non-malignant conditions like uterine artery embolization and thyroid artery embolization.

Revenue is primarily generated from the sale of the TriNav Infusion System, a medical device used in interventional radiology procedures. The company also anticipates future revenue from its investigational immunotherapeutic, nelitolimod.